Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.52 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26614628 | 1.00 | HDAC1 (0.56) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL3952816 | 0.97 | HDAC4 (0.54) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL5329310 | 0.90 | HDAC6 (0.59) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL21241896 | 0.87 | HDAC6 (0.52) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL30060877 | 0.87 | MDM2 (0.48) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL3958560 | 0.86 | HDAC6 (0.71) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL5333748 | 0.86 | HDAC4 (0.57) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL5333743 | 0.86 | HDAC4 (0.57) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL5329050 | 0.85 | HDAC1 (0.70) | HDAC1HDAC6HDAC4HDAC2HDAC3 | |
| SCHEMBL26546948 | 0.84 | HDAC6 (0.60) | HDAC1HDAC6HDAC4HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | HDAC1 378/4885HDAC6 121/4885HDAC4 238/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | HDAC1 1/4885HDAC6 11/4885HDAC4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.